Yu­man­i­ty's ug­ly demise con­tin­ues with plans to axe 60% of staff in search for 's­trate­gic al­ter­na­tives'

Yu­man­i­ty, a one-time neu­rol­o­gy dar­ling that has fall­en far from grace, will fire 60% of its staff as part of a search for “strate­gic al­ter­na­tives” amid the speedy demise of the com­pa­ny’s mar­ket cap, the biotech said in a re­lease.

Yu­man­i­ty said it will take an ex­pan­sive ap­proach to po­ten­tial al­ter­na­tives, pos­si­bly pur­su­ing a re­verse merg­er or out­right ac­qui­si­tion if the mon­ey is right. The biotech went pub­lic in late 2020 as part of a re­verse merg­er deal with an­oth­er strug­gling com­pa­ny, cys­tic fi­bro­sis play­er Pro­teosta­sis Ther­a­peu­tics, but the in­flux of pub­lic cash did noth­ing to stop the bleed­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER